Dephos Chewable Tablet
Sucroferric Oxyhydroxide
500 mg
Eskayef Pharmaceuticals Ltd.
| Pack size | 12's pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 45.00 AED |
Indications
Dephos Chewable Tablet is used for:
Hyperphosphataemia
Adult Dose
Oral
Hyperphosphataemia in chronic kidney disease
Indicated for control of serum phosphorus levels in patients with chronic kidney disease on hemodialysis
Adult: For patients requiring hemodialysis or peritoneal dialysis: Dose is expressed in terms of Fe content; each chewable tab contains 500 mg of Fe (equivalent to 2,500 mg sucroferric oxyhydroxide).
Initially, 1,500 mg (3 tabs) daily in 3 divided doses with meals.
Titrate the dose in increments or decrements of 500 mg daily at intervals of at least 1 week or every 2-4 weeks as needed until acceptable serum phosphorus levels are achieved and with regular monitoring thereafter.
Usual maintenance dose: 1,500-2,000 mg (3-4 tabs) daily in divided doses.
Max: 3,000 mg (6 tabs) daily.
Child Dose
Renal Dose
Administration
Must be administered with meals (adsorbs dietary phosphate in the gut)
To maximize the dietary phosphate binding, the total daily dose should be divided across the meals of the day
Tablets must be chewed and not swallowed whole; to aid with chewing and swallowing, the tablets may be crushed
Contra Indications
Haemochromatosis and other Fe accumulation disorders.
Precautions
Monitor effect and iron homeostasis with patients with peritonitis during peritoneal dialysis, significant gastric or hepatic disorders, following major gastrointestinal surgery, or with a history of hemochromatosis or other diseases with iron accumulation; clinical studies not performed in these groups of patients
Do not prescribe with oral levothyroxine
Do not administer alendronate or doxycycline at the same time; alendronate or doxycycline must be given at least 1 hr before sucroferric oxyhydroxide
Pregnancy-Lactation
Pregnancy
The drug is not systemically absorbed following oral administration; maternal use is not expected to result in fetal exposure to the drug
Animal data
In pregnant rats given up to 800 mg/kg/day by oral gavage from days 6 to 17 post-mating (16 times the maximum recommended clinical dose), no embryo-fetal development toxicity observed.
In pregnant rabbits given 50, 100, or 200 mg/kg/day (corresponding to 4 times the recommended maximum clinical dose) by oral gavage, from days 6 to 19 post-mating, the number of fetuses with incomplete/unossified epiphyses and metacarpals/phalanges was increased at highest dose; litter parameters were not adversely affected
In pregnant rats given Velphoro at 100, 280, or 800 mg/kg/day (16 times the maximum recommended clinical dose) by oral gavage from day 6 post-mating to lactation day 20, offspring body weight gain was lower at age 5-13 weeks and neuromuscular function was delayed at a dose of 800 mg/kg/day
Lactation
This drug is not absorbed systemically following oral administration and breastfeeding is not expected to result in exposure of the child to the drug
Interactions
May decrease the serum concentrations of doxycycline, cefalexin, aspirin, and levothyroxine; administer these agents at least 1 hour before giving sucroferric oxyhydroxide (dosing interval of interacting agents may vary between countries).
Adverse Effects
Side effects of Sucroferric Oxyhydroxide :
>10%
Diarrhea (6-24%)
Discolored feces (12-16%)
1-10%
Nausea (10%)
Mechanism of Action
Sucroferric oxyhydroxide is a mixture of polynuclear iron (III)-oxyhydroxide (pn-FeOOH), sucrose and starches that acts as a phosphate binder. It binds phosphate in the aqueous environment of the gastrointestinal tract by ligand exchange between hydroxyl groups and/or water of sucroferric oxyhydroxide and dietary phosphate. The reduced absorption of dietary phosphate results in decreased levels of serum phosphorus and Ca-phosphorus products.
Note
Dephos 500 mg Chewable Tablet manufactured by Eskayef Pharmaceuticals Ltd.. Its generic name is Sucroferric Oxyhydroxide. Dephos is availble in Bangladesh.
Farmaco BD drug index information on Dephos Chewable Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.